Pneumococcal infection

This study tests an experimental vaccine called V132 in healthy adults aged 50 and older. The goal is to see how safe it is and how well it triggers an immune response compared to existing pneumococcal vaccines. Participants will receive one of several formulations of V132 or a c…

This study tests a new vaccine to protect babies against pneumococcal infections, which can cause pneumonia and meningitis. About 500 healthy infants will receive either the new vaccine or an existing one. Researchers will check if the new vaccine triggers a strong immune respons…

This study tests whether a pneumococcal vaccine (Pneumosil) can produce a strong immune response in children aged 6-59 months who are hospitalised with severe acute malnutrition. Half the children will receive the pneumococcal vaccine, and the other half will receive a typhoid va…

This early-stage study tests a new pneumococcal vaccine (Pn-MAPS30plus) in 60 healthy infants to see if it is safe and what side effects it may cause. Babies will receive three doses starting around 2 months old, followed by a booster at 12-15 months. The study compares the new v…

This study will test whether a new urine-based test can accurately diagnose pneumococcal pneumonia in children under 5 in Malawi. Researchers will use 350 stored urine samples from healthy kids and those with pneumonia, comparing results to standard lab methods. If it works, this…

This study tests whether a simple WhatsApp message reminding people turning 65 in Chile to get their free pneumococcal vaccine can increase vaccination rates. Over 43,000 adults will be randomly assigned to receive the reminder or not, and researchers will track who gets vaccinat…

This large trial will study whether flu and pneumonia vaccines can reduce serious flare-ups and medical costs in people aged 45-80 with COPD. About 7,000 participants will be split into four groups: flu vaccine, pneumonia vaccine, both, or no vaccine. Researchers will track lung …

This study compares two schedules (2+1 vs 3+1 doses) of a 13-valent pneumococcal vaccine in 210 healthy infants starting at 2 months old. Researchers will measure antibody levels and track side effects to find the best way to prevent pneumococcal infections.

This study follows 100 infants who received a pneumococcal vaccine in an earlier trial. Researchers will take a small blood sample to measure antibody levels one and two years after vaccination. The goal is to see how long protection against pneumococcal infections lasts. No new …